D-0371-2022 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0371-2022 was initiated by Teva Pharmaceuticals USA on Dec 31, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 11,450 vials.

Recall details

Product Type
Drugs
Report Date
Jan 19, 2022
Initiation Date
Dec 31, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,450 vials

Product description

Norepinephrine Bitartrate Injection USP 4 mg/4 mL (1 mg/mL), 4 mL Single-Dose Vials, 10 vials per carton, Rx Only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0703-1153-03.

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Methylprednisolone, TN Norepinephrine BItartrate - MS, OH

Code information

Lot # 100020800, exp 07/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0371-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0371-2022. Report a data issue: hello@regdatalab.com.